Printer Friendly

NeoStem licenses exclusive dendritic cells patent from The Rockefeller University.

M2 EQUITYBITES-September 11, 2014-NeoStem licenses exclusive dendritic cells patent from The Rockefeller University


Cellular therapy company NeoStem (NasdaqCM:NBS) Thursday executed an exclusive patent license agreement with The Rockefeller University.

The Rockefeller University patents licensed by NeoStem are titled: "Methods for use of Apoptotic Cells to Deliver Antigen to Dendritic Cells for Induction or Tolerization of T Cells," (inventors: Matthew Albert, Nina Bhardwaj, Ralph M. Steinman, Kayo Inaba and Robert Darnell).

According to the Rockefeller University's studies, the dendritic cells can be removed from the body in their inactive form, loaded with antigens and then re-infused and activated leading to an antigen specific immune response, including immune responses directed against cancer antigens.

This additional intellectual property from The Rockefeller University expands NeoStem's comprehensive Targeted Cancer Immunotherapy Programme patent portfolio, which includes inventions relating to critical aspects of a dendritic cell-based therapy, novel antigen-presenting cancer vaccines, stem cell growth media and methods to produce the high purity cancer initiating (stem) cells that provide the critical antigen array with which the vaccine's dendritic cells are pulsed.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 11, 2014
Previous Article:ProPhase anticipates USD3.6m impairment charge in the Q3 fiscal 2014.
Next Article:Willis Re agrees buy of SurePoint Advisors.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters